A Phase 4 interventional study of Rosuvastatin and Colchicine in Coronary Artery Disease, sponsored by Massachusetts General Hospital. Active, not recruiting at 1 site in United States. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-12.
Sponsored by Massachusetts General Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing rosuvastatin in Coronary Artery Disease — 2 open to participants now, 5 under way, 1 of them phase 3. rosuvastatin · Coronary Artery Disease.
Among the 34 studies testing rosuvastatin in Coronary Artery Disease, this one is the 16th largest by planned enrollment, is the only one that started in 2023, is one of 22 in phase 4, and was the 31st registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →2 of the 34 studies testing rosuvastatin in Coronary Artery Disease are open now, in 2 countries. Recruiting first, the newest first:
Duke University · Sites in United States
Ages 30–60
Prof. Maurovich-Horvat Pál · Sites in Hungary
Ages 45–75
By country, each count listing its studies:
rosuvastatin: first FDA approval 2003 (CRESTOR). What it is approved for, and how studies give it, is on its page →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 175 across the 34 interventional studies. Of the 14 that completed or were terminated, 3 (21%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 34 have an industry lead sponsor. The 10 most frequent:
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 445 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
16 studies in Coronary Artery Disease by Massachusetts General Hospital: 2 open now, 5 under way, none of them phase 3. Of 8 finished, 7 (88%) have results posted.
Among the 16 studies in Coronary Artery Disease by Massachusetts General Hospital, this one is the 3rd largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2023, is one of 5 in phase 4, and was the 13th registered.
Massachusetts General Hospital’s Coronary Artery Disease studies by the year they started, since 2006.
3 of the studies testing rosuvastatin in Coronary Artery Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03169985Samsung Medical CenterRandomized Controlled Trial of Moderate-Intensity Rosuvastatin With Ezetimibe Combination Therapy Versus High-Intensity Rosuvastatin on Progression of Coronary Atherosclerotic Plaque | 2027-01-28 |
| NCT05850091Massachusetts General HospitalPolygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine | 2027-06-01 |
| NCT06767345Korea University Anam HospitalComparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization | 2027-11 |
Add all 3 to your calendar (.ics) → With an account.
Among the 34 studies testing rosuvastatin in Coronary Artery Disease, from their registry updates:
Among Massachusetts General Hospital’s 16 in Coronary Artery Disease:
This tab as a report to print or save as PDF → With an account.
The goal of this double-blind randomized controlled trial is to determine how treatment with high intensity statin, low-dose colchicine, and their combination modulates progression and composition of coronary atherosclerosis in individuals with high polygenic risk for coronary artery disease.
The main question PROACT 2 aims to answer is whether and how single or dual targeting of cholesterol-lowering and inflammation modulates coronary plaque in individuals with high polygenic risk and subclinical coronary atherosclerosis.
This is a double-blind randomized controlled trial of 200 individuals with high polygenic risk for coronary artery disease and subclinical plaque on coronary computed tomography angiography. Participants will be randomized into four equal treatment groups: group A receiving a placebo daily, group B receiving rosuvastatin 20mg daily, group C receiving colchicine 0.6mg daily, and group D receiving both rosuvastatin 20mg daily and colchicine 0.6mg daily. The primary outcome is change in total non-calcified plaque volume on coronary computed tomography angiography from baseline to one year. Multiple secondary plaque imaging and biomarker outcomes will be explored in this pilot mechanistic trial.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive placebo daily
Drug: Placebo
Participants will receive rosuvastatin 20mg daily and placebo daily
Drug: Rosuvastatin · Drug: Placebo
Participants will receive colchicine 0.6mg daily and placebo daily
Drug: Colchicine · Drug: Placebo
Participants will receive rosuvastatin 20mg daily and colchicine 0.6mg daily
Drug: Rosuvastatin · Drug: Colchicine
Pharmacotherapy for reduction in LDL cholesterol level
Pharmacotherapy for inflammation inhibition
Capsule with sugar pill that mimics active study drugs
Change in total non-calcified plaque volume from baseline to one year
The primary outcome of this study is the change in total non-calcified plaque volume between the two groups from baseline to one year. This outcome will be measured using coronary computed tomography angiography (CCTA) and reported in cubic millimeters (mm³). The comparison of the changes in non-calcified plaque volume will help assess the effectiveness of the intervention on plaque progression and composition.
Time frame: 1 year
Change in total plaque volumes from baseline to one year
The change in the following plaque volumes will be compared between the two groups from baseline to one year: total plaque volume, total calcified plaque volume, and total low attenuation plaque volume. These volumes will be analyzed individually and reported in cubic millimeters (mm³).
Time frame: 1 year
Change in maximal luminal stenosis from baseline to one year
The change in maximal luminal stenosis will be compared between the two groups from baseline to one year, reported as a percentage (%).
Time frame: 1 year
Change in calcium score from baseline to one year
The change in calcium score will be compared between the two groups from baseline to one year, reported in Agatston units.
Time frame: 1 year
Change in number of high-risk features from baseline to one year
The change in the number of high-risk features will be compared between the two groups from baseline to one year, reported as a count (number of features).
Time frame: 1 year
Change in fat attenuation index from baseline to one year
The change in fat attenuation index will be compared between the two groups from baseline to one year, reported in Hounsfield units (HU).
Time frame: 1 year
Progression in non-calcified plaque volume from baseline to one year
The proportion of participants who had progression in non-calcified plaque volume from baseline to one year (%)
Time frame: 1 year
Change in low-density lipoprotein cholesterol (LDL-C) from baseline to one year
The change in low-density lipoprotein cholesterol (LDL-C) will be compared between the two groups from baseline to one year, reported in milligrams per deciliter (mg/dL).
Time frame: 1 year
Change in C-reactive protein (CRP) from baseline to one year
The change in C-reactive protein (CRP) will be compared between the two groups from baseline to one year, reported in milligrams per liter (mg/L).
Time frame: 1 year
Change in Interleukin-6 and Interleukin-1 beta (IL-1ß) from baseline to one year
The change in Interleukin-6 (IL-6) and Interleukin-1 beta (IL-1ß) will be compared between the two groups from baseline to one year. Both biomarkers will be analyzed individually and reported in picograms per milliliter (pg/mL).
Time frame: 1 year
Plan to share: Yes — Data will be tabulated and analyzed. Study site will not share any of the subject identifiers.
Started Dec 2023 (actual). Primary completion is estimated for Jun 2027, 41 months after the start.
Of 181 non-industry phase 4 interventional studies under Coronary Artery Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 41 months is above that.
Counting every sponsor, half of 194 studies reached it within 35 months; a quarter within 20 and three quarters within 58.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rosuvastatin · Colchicine
Massachusetts General Hospital →